ES2154744T3 - Formulaciones de comprimidos farmaceuticos para compresion directa. - Google Patents
Formulaciones de comprimidos farmaceuticos para compresion directa.Info
- Publication number
- ES2154744T3 ES2154744T3 ES95942265T ES95942265T ES2154744T3 ES 2154744 T3 ES2154744 T3 ES 2154744T3 ES 95942265 T ES95942265 T ES 95942265T ES 95942265 T ES95942265 T ES 95942265T ES 2154744 T3 ES2154744 T3 ES 2154744T3
- Authority
- ES
- Spain
- Prior art keywords
- direct compression
- formulations
- pharmaceutically active
- active principle
- pharmaceutical tablets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
LOS COMPRIMIDOS SE PRODUCEN COMPRIMIENDO DIRECTAMENTE UNA MEZCLA FORMADA MEZCLANDO EN SECO UN PRINCIPIO FARMACEUTICAMENTE ACTIVO, LACTOSA PARA COMPRESION DIRECTA, UN LUBRICANTE COMO ESTEARATO DE MAGNESIO Y UN INHIBIDOR, ESPECIALMENTE ALMIDON DE MAIZ. EL PRINCIPIO FARMACEUTICAMENTE ACTIVO INCLUYE OXIBUTININA, BUMETANIDA, INDAPAMIDA Y EN PARTICULAR SELEGILINA. EL INHIBIDOR PREVIENE LA INTERACCION ENTRE LA LACTOSA PARA COMPRESION DIRECTA Y EL PRINCIPIO FARMACEUTICAMENTE ACTIVO.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IE940969 | 1994-12-14 | ||
| IE940971 | 1994-12-14 | ||
| IE950584 | 1995-07-31 | ||
| IE950583 | 1995-07-31 | ||
| IES950586 IES65615B2 (en) | 1995-07-31 | 1995-07-31 | Pharmaceutical processing |
| PCT/IE1995/000062 WO1996018386A1 (en) | 1994-12-14 | 1995-12-14 | Pharmaceutical tablet formulations for direct compression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2154744T3 true ES2154744T3 (es) | 2001-04-16 |
Family
ID=27517559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES95942265T Expired - Lifetime ES2154744T3 (es) | 1994-12-14 | 1995-12-14 | Formulaciones de comprimidos farmaceuticos para compresion directa. |
Country Status (11)
| Country | Link |
|---|---|
| EP (2) | EP1057479A1 (es) |
| AT (1) | ATE199495T1 (es) |
| AU (1) | AU4353996A (es) |
| DE (1) | DE69520292T2 (es) |
| DK (1) | DK0800384T3 (es) |
| ES (1) | ES2154744T3 (es) |
| GB (1) | GB2295966B (es) |
| GR (1) | GR3035863T3 (es) |
| IE (1) | IE950946A1 (es) |
| PT (1) | PT800384E (es) |
| WO (1) | WO1996018386A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL197077B1 (pl) * | 1998-12-01 | 2008-02-29 | Reddys Lab Inc Dr | Kompozycja farmaceutyczna zawierająca 5-[[4-[3-metylo-4-okso-3,4-dihydro-2-chinazolinylo]metoksy]fenylometylo]-tiazolidyno-2,4-dion lub jego sól dopuszczalną do stosowania w farmacji i sposób jej wytwarzania |
| WO2001091751A1 (en) * | 2000-05-30 | 2001-12-06 | Novo Nordisk A/S | New pharmaceutical composition and the process for its preparation |
| AU2001260083A1 (en) * | 2000-05-26 | 2001-12-03 | Dr. Reddy's Research Foundation | New pharmaceutical composition and the process for its preparation |
| AU2005202705B2 (en) * | 2000-12-06 | 2006-06-15 | Novartis Ag | Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
| US7049283B2 (en) | 2000-12-06 | 2006-05-23 | Novartis Ag | Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
| RU2207128C2 (ru) * | 2001-07-05 | 2003-06-27 | Закрытое акционерное общество "ВЕРОФАРМ" | Диуретическое и гипотензивное средство |
| RU2191572C1 (ru) * | 2001-09-26 | 2002-10-27 | Нестерук Владимир Викторович | Диуретическое и гипотензивное средство в виде таблетки |
| PL193976B1 (pl) * | 2002-07-01 | 2007-04-30 | Pliva Krakow | Tabletka o przedłużonym działaniu zawierająca indapamid i sposób wytwarzania tabletki o przedłużonym działaniu zawierającej indapamid |
| RU2286779C2 (ru) * | 2003-02-06 | 2006-11-10 | Закрытое акционерное общество "Фармацевтическое предприятие "Оболенское" | Лекарственная форма, обладающая диуретическим и антигипертензивным действием, и способ ее изготовления |
| DE102004005009A1 (de) * | 2004-01-30 | 2005-09-01 | Krka Tovarna Zdravil, D.D. | Verzögert freisetzende pharmazeutische Zusammensetzung von Indapamid |
| DE102004062257A1 (de) | 2004-12-23 | 2006-07-06 | Merckle Gmbh | Direkt verpresste Indapamid-Tabletten mit verzögerter Wirkstofffreisetzung |
| NZ701505A (en) | 2005-10-25 | 2016-06-24 | Resmed Ltd | Interchangeable mask assembly |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4517179A (en) * | 1983-04-29 | 1985-05-14 | Pennwalt Corporation | Rapid dissolving, uniform drug compositions and their preparation |
| US4639458A (en) * | 1985-01-22 | 1987-01-27 | Merck & Co., Inc. | Tablet and formulation |
| ATE92752T1 (de) * | 1987-07-08 | 1993-08-15 | American Home Prod | Spruehgetrocknete ibuprofen-zusammensetzungen. |
| US4792452A (en) * | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| HU208484B (en) * | 1988-08-17 | 1993-11-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia |
| US5047246A (en) * | 1988-09-09 | 1991-09-10 | Bristol-Myers Company | Direct compression cyclophosphamide tablet |
| DE3941703C2 (de) * | 1989-12-18 | 2002-11-07 | Sanol Arznei Schwarz Gmbh | Bumetanid enthaltende pharmazeutische Zubereitung |
| US5358717A (en) * | 1989-12-22 | 1994-10-25 | Syntex (U.S.A.) Inc. | Directly-compressible naproxen or naproxen sodium compositions |
| US5057321A (en) * | 1990-06-13 | 1991-10-15 | Alza Corporation | Dosage form comprising drug and maltodextrin |
| FR2669221B1 (fr) * | 1990-11-15 | 1993-01-15 | Rhone Poulenc Sante | Procede de preparation par compression directe de comprimes de derives de l'acide cephalosporanique. |
| SK117793A3 (en) * | 1991-04-29 | 1994-05-11 | Merck & Co Inc | Optimized tablet formulation |
| FR2677886B1 (fr) * | 1991-06-18 | 1995-03-31 | Adir | Comprime matriciel permettant la liberation prolongee d'indapamide apres administration par voie orale. |
| DE69326848T2 (de) * | 1992-05-13 | 2000-01-27 | Alza Corp | Oxybutynin zur transdermalen Verabreichung |
| US5358941A (en) * | 1992-12-02 | 1994-10-25 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids with lactose |
| SE9301112D0 (sv) * | 1993-04-02 | 1993-04-02 | Orion-Yhtymae Oy | A new composition |
| CA2125251C (en) * | 1993-06-07 | 2005-04-26 | Yoshiyuki Inada | A pharmaceutical composition for angiotensin ii-mediated diseases |
| AU6971294A (en) * | 1993-06-08 | 1995-01-03 | Novartis Ag | Process for the preparation of an oral solid dosage form containing diclofenac |
| ZA939566B (en) * | 1993-12-21 | 1994-08-11 | Applied Analytical Ind Inc | Method for dry blend compression od medicaments. |
-
1995
- 1995-12-14 WO PCT/IE1995/000062 patent/WO1996018386A1/en not_active Ceased
- 1995-12-14 DK DK95942265T patent/DK0800384T3/da active
- 1995-12-14 AU AU43539/96A patent/AU4353996A/en not_active Abandoned
- 1995-12-14 EP EP00115840A patent/EP1057479A1/en not_active Withdrawn
- 1995-12-14 GB GB9525598A patent/GB2295966B/en not_active Expired - Fee Related
- 1995-12-14 AT AT95942265T patent/ATE199495T1/de not_active IP Right Cessation
- 1995-12-14 EP EP95942265A patent/EP0800384B1/en not_active Expired - Lifetime
- 1995-12-14 DE DE69520292T patent/DE69520292T2/de not_active Expired - Fee Related
- 1995-12-14 ES ES95942265T patent/ES2154744T3/es not_active Expired - Lifetime
- 1995-12-14 PT PT95942265T patent/PT800384E/pt unknown
- 1995-12-14 IE IE950946A patent/IE950946A1/en not_active IP Right Cessation
-
2001
- 2001-05-15 GR GR20010400714T patent/GR3035863T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DK0800384T3 (da) | 2001-04-17 |
| GB9525598D0 (en) | 1996-02-14 |
| IE950946A1 (en) | 1996-06-26 |
| WO1996018386A1 (en) | 1996-06-20 |
| GB2295966A (en) | 1996-06-19 |
| DE69520292T2 (de) | 2001-06-13 |
| GB2295966B (en) | 1997-09-24 |
| GR3035863T3 (en) | 2001-08-31 |
| DE69520292D1 (de) | 2001-04-12 |
| PT800384E (pt) | 2001-06-29 |
| EP0800384B1 (en) | 2001-03-07 |
| ATE199495T1 (de) | 2001-03-15 |
| EP0800384A1 (en) | 1997-10-15 |
| EP1057479A1 (en) | 2000-12-06 |
| AU4353996A (en) | 1996-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2096103T3 (es) | Preparacion de comprimidos de resistencia incrementada. | |
| ES2154744T3 (es) | Formulaciones de comprimidos farmaceuticos para compresion directa. | |
| AR002355A1 (es) | Composiciones y metodos para administracion local de agentes farmaceuticamente activos. | |
| ES2091737T3 (es) | Formulaciones farmaceuticas de fluoxetina. | |
| ES2167061T3 (es) | Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino. | |
| ES2138271T3 (es) | Compuestos de 6-dimetil-amino-metil-1-fenil-ciclohexano como principio activo farmaceutico. | |
| MXPA04005105A (es) | Formulaciones de acitromicina directamente compresibles. | |
| AR032293A1 (es) | Estuche farmaceutico | |
| TR200102977T2 (tr) | Yeni tedavi yöntemi. | |
| AR014133A1 (es) | Procedimiento para fabricar tabletas de dispersion rapida para administracion oral y una formulacion de dichas tabletas | |
| AR010634A1 (es) | Composicion farmaceutica en forma de una solucion para la administracion de inhibidores de proteasa hiv | |
| ES2165640T3 (es) | Acidos diaminocarboxilicos sustituidos. | |
| ES2195220T3 (es) | Acidos sulfonilaminocarboxilicos. | |
| PA8606201A1 (es) | DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN | |
| GR1003530B (el) | Ταχεως διαλυομενες συνθεσεις εχουσες αναλγητικη δραση | |
| ES2195638T3 (es) | Preparaciones de combinaciones farmaceuticas en forma solida de dosificacion que contienen cardevilol e hidroclorotiazida. | |
| CO4940406A1 (es) | Composiciones de paracetamol de accion rapida | |
| ES2160680T3 (es) | Utilizacion de un antagonista de sustancia p en una composicion farmaceutica. | |
| ECSP930933A (es) | Composicion farmaceutica y procedimiento para prepararla | |
| CO4410176A1 (es) | Formulaciones farmaceuticas de cefaclor | |
| ES2174293T3 (es) | Microesferas farmaceuticas de acido valproico para la administracion oral. | |
| MXPA03005705A (es) | Producto para el cuidado de la piel conteniendo retinoides y fitoestrogenos en un paquete de compartimiento dual. | |
| ES2063412T3 (es) | Tableta y granulado que contienen como principio activo mesna. | |
| TR200200978T2 (tr) | Yeni mirtazapin formülasyonu | |
| AR036755A1 (es) | Una composicion en forma de gel transparente para la administracion de diclofenac sodico a traves de la piel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 800384 Country of ref document: ES |